TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Ghrelintrial With Patients With Stroke

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients~* acute ischemic insult~* functionally relevant motor hemisymptomatic~* up to 7 days after the event~* age from 18 to 90 years~* written approval of the participant after occurred clarification~Exclusion Criteria:~* Dysphagia~* Nutritional-Risk-Screening (NRS) = 3~* Neuro-degenerative illnesses~* Patients with strokes in the past~* Patients with clinically relevant Polyneuropathy~* Patients with walking disturbance on account of mikroangiopathic changes~* Patients with psychiatric preillnesses (depression, schizophrenia) and anti- depressive and neuroleptic medication~* Patients with rheumatic illnesses with effects on the walking and Hand function~* Patients with innate and/or acquired substance defects of the brain and/or spinal cord (functionally relevant brain tumour, St. n. Encephalitis, brain damage as an infant)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Anterolateral Versus Posterior Approach for Total Hip Arthroplasty After Displaced Femoral Neck Fracture

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Displaced femoral neck fracture~* Age 65 years or older~* Acute, femoral neck fracture~Exclusion Criteria:~Cognitive impairment~* Active Infection~* Limited functional capacity (nursing home resident, non-ambulatory, severe cardiorespiratory disease)~* Limited life expectancy~* Pathologic fracture (tumor)~* Acetabular fractures

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- anterolateral approach (Type: OTHER): surgical intervention THA anterolateral approach
- posterior approach (Type: OTHER): surgical intervention THA posterior approach

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of the Ulcerative Colitis Diet for Induction of Remission

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent~* Established diagnosis of UC disease.~* Age: 5 - 18 years ( inclusive)~* Mild to moderate active disease, 10 ≤ PUCAI ≤45.~* Stable medication (IMM/ 5ASA) use for the past 6 weeks.~* For patients who received antibiotic treatment: age 10-18 (inclusive).~Exclusion Criteria:~* Any proven infection such as positive stool culture, parasite or C.difficile.~* Use of Antibiotics~* Use of steroids in the previous two weeks only~* Patients that are refractory to full dose steroids ( 1 mg/kg/day)~* Past acute severe UC.~* Current Extra intestinal manifestation of UC.~* Pregnancy.~A subset of patients who are on steroids and relapse during steroids treatment ≤0.5 mg/kg with mild to moderate disease activity will act as a second subset for this exploratory study.~-

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Ulcerative Colitis Diet counseling (Type: EXPERIMENTAL): Patients will receive a structured novel diet termed the UCD for 6 weeks. . patients that completed induction phase with remission(PUCAI\<10) will be asked if they are willing to adhere to the UCD for an additional 20 weeks.
- Antibiotic Treatment (Type: EXPERIMENTAL): Patients failing to enter or maintain remission by 6 weeks, or with worsening disease at any time after week 2 will be considered failures on an intention to treat basis. Eligible patients at this time at aged 10 or above may receive a 14 day antibiotic course with Doxycycline, amoxicillin and metronidazole.In addition to the description above children who refused to UCD or with low adherence to UCD may be enrolled directly to this arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Effect of FLUTTER® VRP1 (PEP and Oscillating High Frequency).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Non Cystic Fibrosis Bronchiectasis~* Amount of secretion sufficient for analysis~* Capable of fulfilling the experimental protocol~Exclusion Criteria:~* Acute pulmonary disease~* Presence of any respiratory infection in the last four weeks

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Flutter group (Type: ACTIVE_COMPARATOR): In Flutter group the exercise used the Flutter ®VRP1 (VarioRaw SA, Switzerland).
- PEP group (Type: ACTIVE_COMPARATOR): In PEP group the exercise used the Flutter ®VRP1 (VarioRaw SA, Switzerland) without the steel ball inside, with the closure of so many holes as necessary to produce a positive expiratory pressure equivalent to pressure achieved by patients during the performance with the ball in the Flutter®VRP1.
- control group (Type: PLACEBO_COMPARATOR): In placebo patients were assessed as pulmonary function, respiratory muscle strength and transport properties of respiratory secretions
- Group Sham (Type: SHAM_COMPARATOR): Exercise with Flutter®VRP1 without the ball inside

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Circulating Adenosine Levels Before and After Intravenous (IV) Persantine

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects with or without coronary artery disease undergoing a Persantine nuclear stress test~Exclusion Criteria:~* Oral persantine use within 24 hours~* Second or third degree AV block, or sick sinus syndrome without a functioning pacemaker~* Active asthma or bronchospasm~* Those with end-stage liver disease such as cirrhosis or active hepatitis such as \> 5 fold liver enzyme elevation will not be included~* Anemia (Hct \< 30)~* Myocardial infarction within 30 days~* Severe left ventricular dysfunction (EF \< 30%)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- undergoing persantine stress test (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: TTNS Versus Sham Therapy for Children With iOAB (TaPaS Part I)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children between 5 and 12 years old, clinically diagnosed with the idiopathic overactive bladder syndrome with urinary incontinence (daytime and/or nighttime)~* Untreated, except from urotherapy.~Exclusion Criteria:~* Enuresis nocturna due to nocturnal polyuria~* Dysfunctional voiding~* Neurogenic bladder~* Psychiatric disorders, behavioural disturbances or mental disabilities~* Treated before with pharmacotherapy or invasive therapies for OAB~* Children with parents unable to record reliably micturition diaries.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Active TTNS (Type: ACTIVE_COMPARATOR): Children treated by transcutaneous tibial nerve stimulation. TENS device connected to adhesive electrodes. Stimulation settings: 200 µS, 20 Hz, 1-20 V ( depending of sensory response) Home-therapy: Daily stimulation during 60 minutes.
- TTNS sham intervention (Type: SHAM_COMPARATOR): Children treated by TTNS with same positioning as the active TTNS treatment. Stimulation settings: 200 µS, 20 Hz, 0-1 V. Patients and parents will be told that electric currence is given, but that no sensation will be feld.~Home therapy: Daily stimulation during 60 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Adaptive Device for Insulin Pens for Arthritic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Currently using a pen to administer medication at least once a week~* Currently are having some difficulty (self reported) using their pens because of dexterity issues~Exclusion Criteria:~* Woman of child-bearing age who are known to be pregnant~* People who are unable or unwilling to sign the informed consent document~* Patients who do not understand the proper use of the device after sufficient instruction~* Anyone in the Principal Investigator's judgment who cannot properly use the device

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (pen device) (Type: EXPERIMENTAL): Subjects will use the pen device when using their commercially available insulin pens
- Control (Type: NO_INTERVENTION): Subjects will use the commercially available insulin pens only (no adaptive pen device).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Rosuvastatin Interethnic PK Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects that are scheduled for bariatric surgery.~* Subjects that are able and willing to donate surplus intestinal tissue.~* Subjects with solute carrier organic anion transporter \*1 (SLCO1B1) and breast cancer resistant protein (BCRP) 421CC genotypes.~* White/Caucasian/European and Asian/East Asian heritage individuals, male or female, 18 years of age or older.~* BMI between 30-55 kg/m2~* Be able to read, speak, and understand English(UCSF) and Chinese(Taiwan).~* Subjects capable of providing informed consent and completing the requirements of the study.~Exclusion Criteria:~* Subjects with active liver and kidney problems, severe cardiovascular diseases, type I diabetes, advanced pulmonary disease, and cancers.~* Subjects on chronic prescription or over the counter medication that have previously been reported to exhibit drug-drug interactions with rosuvastatin and cannot be stopped two weeks prior to and during the study, including gemfibrozil, cyclosporine, atazanavir, lopinavir and ritonavir.~* Subjects incapable of multiple blood draws (HCT \< 30mg/dL).~* Subjects with a history of rhabdomyolysis.~* Subjects with a history of drug-related myalgias.~* Subjects with a history or diagnosis of hemorrhagic tendencies or blood dyscrasias.~* Subjects with a history of GI bleed or peptic ulcer disease.~* Subjects with a recent history of trauma.~* Subjects who smoke tobacco or have ongoing alcohol or illegal drug use.~* Subjects who are pregnant, lactating, or trying to conceive during the study period.~* Subjects allergic to rosuvastatin or any known component of the medications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Asians (Type: EXPERIMENTAL): Drug: Rosuvastatin Rosuvastatin 20mg po x1 Other Name: Crestor
- Caucasians (Type: EXPERIMENTAL): Drug: Rosuvastatin Rosuvastatin 20mg po x1 Other Name: Crestor

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Marijuana for Cancer Pain

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
INCLUSION CRITERIA~* Have ongoing cancer pain~* Be diagnosed with cancer and have at least a six month survival.~* Be on a stable dose of opioid medication for at least 2 weeks before enrollment.~* Have smoked marijuana on at least 6 occasions in their lifetime prior to enrollment.~EXCLUSION CRITERIA~You must not:~* Start chemotherapy, radiation or biphosphonates during the study, or have received any new intervention with any such agents within the past 4 weeks.~* Currently be using smoked tobacco products.~* Currently be in methadone treatment.~* Have smoked marijuana within 30 days of enrollment.~* Be diagnosed with diabetes mellitus.~* Have severe heart disease, uncontrolled hypertension, or lung disease.~* Currently be receiving treatment with corticosteroids.~* Be pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Adolescent Major Depression

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* mild to moderate level depressive symptoms (RBDI self-report scale)~* adequate knowledge of the Finnish language~* informed consent from the adolescent (all) and his/her parent (under 15 years)~* healthy controls comprise subjects with no depressive symptoms~Exclusion Criteria:~* ongoing major depression, dysthymia or bipolar disorder~* ongoing other severe psychiatric illness precluding group participation~* mental retardation

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Group cognitive intervention (the Adolescent Coping with Stress)
- 2 (Type: ACTIVE_COMPARATOR): Treatment as usual
- 3 (Type: ACTIVE_COMPARATOR): Healthy controls, receive usual health education in school health care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Role of Children in Transmission of COVID-19 to Immunocompromised Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Immunocompromised patient followed at UCLA Health~* Immunocompromised patient \>1 day old to \<60 years of age~* Patient with a diagnosis of breast, lung, or colorectal cancers, lymphoma, acute/chronic leukemia, multiple myeloma, or other solid tumors and are receiving chemotherapy~* Patients who have received a hematopoietic stem cell transplantation within the last year~* Patients who have received a solid organ transplantation within the last year~Exclusion Criteria:~* Immunocompromised patients with positive SARS-CoV-2 test prior to study enrollment

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Families with Children (Type: None): Families containing an immunocompromised individual that have children in the family setting.
- Famlies without children (Type: None): Families containing an immunocompromised individual that do not have children in the family setting.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance Regimen

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-infected as documented by positive HIV antibody test and confirmed by Western Blot.~* Subject is in need for a switch in maintenance regimen due to adverse effects, toxicities, simplification and/or resistance.~* Subject is at least 18 years of age at the day of screening.~* Subject is able and willing to sign the Informed Consent Form prior to screening evaluations.~* HIV-1 RNA \< 40 copies/mL for at least 6 months on antiretroviral therapy prior to inclusion.~* Subject has no documented resistance mutations to PIs, INSTIs or lamivudine.~Exclusion Criteria:~* Documented history of sensitivity/idiosyncrasy to medicinal products or excipients.~* Relevant history or current condition that might interfere with drug absorption, distribution, metabolism or excretion.~* Inability to understand the nature and extent of the trial and the procedures required.~* Pregnant female (as confirmed by an HCG test performed less than 3 weeks before the first dose) or breast-feeding female.~* Abnormal serum transaminases determined as levels being \> 5 times upper limit of normal.~* Renal failure determined as an estimated Glomerular Filtration Rate (eGFR) \< 50 ml/min (MDRD-based).~* Concomitant use of medications that interfere with atazanavir, dolutegravir or lamivudine pharmacokinetics: oxcarbazepine, phenytoin, phenobarbital, carbamazepine, St. John's wort, rifampicin, clarithromycin, H2 receptor antagonists, proton pump inhibitors, irinotecan, midazolam, triazolam, buprenorphine, aprepitant, modafinil, imatinib, co-trimoxazole, other antiretroviral drugs.~* Concomitant use of medications that are contraindicated for use with atazanavir, dolutegravir or lamivudine: alfuzosin, dofetilide, pimozide, quetiapine, quinidine, bepridil, simvastatin, atorvastatin, lovastatin, sildenafil (as for use in pulmonary arterial hypertension), cladribine.~* Active hepatobiliary or hepatic disease (including chronic hepatitis B or C infection).~* Alcohol abuse.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PRADAII regimen (Type: EXPERIMENTAL): Use of PRADAII regimen during 12 weeks. This regimen consists of atazanavir 400 mg QD, dolutegravir 50 mg QD, lamivudine 300 mg QD.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study: Paravertebral Analgesia vs Epidural Analgesia After Thoracotomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Open thoracotomy~* Age \> 18 yo~* Able to use a patient controlled analgesia device~Exclusion Criteria:~* Previous thoracotomy~* Previous spine surgery~* Chronic pain condition~* Ongoing narcotic use~* Prior narcotic abuse~* Active chest infection~* Chest trauma~* Anticoagulation~* Other contraindication to epidural catheter placement~* Allergy to local anesthetic or narcotic

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Epidural Catheter 0.2% ropivacaine (Type: ACTIVE_COMPARATOR): Patients will receive an infusion of 0.2% ropivacaine at a range of 0-10 mL/hr through an epidural catheter. They will also receive an infusion of saline at a rate of 0-10 mL/hr through a paravertebral catheter.
- Paravertebral Catheter 0.4% ropivacaine (Type: ACTIVE_COMPARATOR): Patients will receive an infusion of 0.4% ropivacaine at a range of 0-10mL/hr through a paravertebral catheter. They will also receive an infusion of saline at a range of 0-10mL/hr through an epidural catheter.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Tomotherapy on Xerostomia and Quality of Life of Patients With Cancer of the Upper Aero-digestive Tract

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient (e) old (e) over 18 years~* Patients with squamous cell carcinoma of head and neck (oral cavity, oropharynx, lymphadenopathy without gateway) histologically proven.~* Patient targeted for head and neck radiotherapy by Tomotherapy exclusive with or without concurrent chemotherapy (containing platinum)~* Indication of head and neck radiotherapy bilateral~* All of the TNM stage except metastatic~* Patient has signed informed consent for participation in the study~* Mastery of the French language~Exclusion Criteria:~* History of head and neck radiotherapy~* Indication of head and neck radiotherapy unilateral~* Personal history of malignant tumors uncontrolled over the past 5 years~* History of oral sicca syndrome~* Surgical removal of one or more salivary glands (parotid, submandibular gland, sublingual gland)~* Concomitant treatment with amifostine~* Concomitant treatment with cetuximab~* Primary tumor of the salivary glands~* Head and neck hyperfractionated radiotherapy and / or accelerated~* Head and neck radiotherapy hypofractionated~* Metastatic disease~* Patient deprived of liberty, under guardianship~* Any medical condition or psychological associate that could compromise the patient's ability to participate in the study~* Refusal of the patient.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy